A Study of Zilovertamab Vedotin in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care